Place in therapy of cyclin-dependent kinase 4/6 inhibitors in breast cancer: A targeted literature review
M Zhao, KA Hanson, Y Zhang, A Zhou, AS Cha-Silva - Targeted Oncology, 2023 - Springer
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) are the preferred regimen for patients
with hormone receptor-positive and human epidermal growth factor receptor 2-negative …
with hormone receptor-positive and human epidermal growth factor receptor 2-negative …
Real world incidence and management of adverse events in patients with HR+, HER2− metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States …
GL Price, L Sudharshan, P Ryan… - Current Medical …, 2022 - Taylor & Francis
Objective To examine the real-world incidence and management of select adverse events
(AEs) among female patients with hormone receptor positive (HR+), human epidermal …
(AEs) among female patients with hormone receptor positive (HR+), human epidermal …
Sticking to the rules: outcome and success rate of guideline-based diarrhea management in metastatic breast cancer patients treated with abemaciclib
F Jacobs, E Agostinetto, A Solferino, R Torrisi… - Journal of Clinical …, 2023 - mdpi.com
In clinical trials testing abemaciclib in patients with hormone-receptor-positive (HR+), HER2-
negative (HER2-) advanced breast cancer, diarrhea is a very common adverse event …
negative (HER2-) advanced breast cancer, diarrhea is a very common adverse event …
[图书][B] Advances of benzimidazole derivatives as anticancer agents: bench to bedside
Benzimidazole is one of the privileged nitrogen-containing scaffolds known for its versatile
diversified role in insecticides, pesticides, dyes, pigments and pharmaceuticals. Due to its …
diversified role in insecticides, pesticides, dyes, pigments and pharmaceuticals. Due to its …
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
E Zattarin, L Mariani, A Menichetti… - Therapeutic …, 2023 - journals.sagepub.com
Background: Cyclin-Dependent Kinase 4/6 inhibitors (CDK4/6i) combined with Endocrine
Therapy (ET) are the standard treatment for patients with Hormone Receptor-positive/HER2 …
Therapy (ET) are the standard treatment for patients with Hormone Receptor-positive/HER2 …
Theranostics platform of Abemaciclib using magnetite@ silica@ chitosan nanocomposite
The current study was designed to synthesize a nanoformula comprising of magnetite
nanoparticles (MN) with mesoporous silica (MS), which was in turn coated with chitosan …
nanoparticles (MN) with mesoporous silica (MS), which was in turn coated with chitosan …
Real-world patient characteristics, utilization patterns, and outcomes of US patients with HR+, HER2− metastatic breast cancer treated with abemaciclib
EN Smyth, J Beyrer, KR Saverno, E Hadden… - Drugs-Real World …, 2022 - Springer
Background Abemaciclib is the most recent oral cyclin-dependent kinase 4 and 6 inhibitor
(CDK4 & 6i) to receive US Food and Drug Administration (FDA) approval to treat hormone …
(CDK4 & 6i) to receive US Food and Drug Administration (FDA) approval to treat hormone …
[HTML][HTML] Real-world treatment outcomes in HR+ HER2-metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil
MM Queiroz, KP Sacardo, MF Ribeiro… - Cancer Treatment and …, 2023 - Elsevier
Abstract Background Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have been recently
developed and introduced into clinical practice. Methods We retrospectively analyzed data …
developed and introduced into clinical practice. Methods We retrospectively analyzed data …
Abemaciclib-associated diarrhea: an exploratory analysis of real-life data
Background/Aim: Abemaciclib is a cyclin-dependent kinase 4/6 inhibitor approved in
combination with endocrine therapy for treating hormone receptor-positive and human …
combination with endocrine therapy for treating hormone receptor-positive and human …
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2-metastatic breast cancer patients in Japan
K Nozawa, M Terada, M Onishi, Y Ozaki, T Takano… - Breast Cancer, 2023 - Springer
Introduction This study described, in routine clinical practice in Japan, the patient
characteristics, treatment patterns, and outcomes of female patients with HR+/HER2 …
characteristics, treatment patterns, and outcomes of female patients with HR+/HER2 …